Let’s Talk About Lung NETs

Neuroendocrine tumors (NETs) are less common than other types of lung cancer but recognized with increased frequency due to advances in imaging technology and the advent of lung cancer screening. (Dasari 2017.) Lung NETs are classified into four different categories with vastly different courses. Some are slow growing; others are more aggressive. Certain lung NETs occur in nonsmokers and light smokers, while others are associated with heavy smoking.

Information about Lung NETs

As with other NETs, the diagnosis of lung NETs can be challenging. Some patients do not show any signs of illness. Those with symptoms, such as coughing, wheezing, or tightness in the chest, may be diagnosed with more common illnesses, such as asthma. Since lung NETs develop in hormone-producing cells, a few patients experience symptoms unrelated to the lungs, such as diarrhea or flushing in the face.

Location and Classification of Lung NETs

Lung NETs are divided into four subtypes:

  • Typical carcinoid (TC)
  • Atypical carcinoid (AC)
  • Large cell neuroendocrine carcinoma (LCNC)
  • Small cell lung cancer (SCLC)

“When we are classifying lung NETs we want to make one basic distinction,” said Suki Padda, MD, Stanford University, “Is this a well-differentiated lung NET, which includes low-grade typical carcinoid, or intermediate grade atypical carcinoid, or is this a poorly differentiated lung NET and that includes SCLC and LCNC?” The outlook for each is different. Learn more about how lung NETs are classified in this talk by Dr. Suki Padda, Stanford University.

“Large cell neuroendocrine carcinoma and small cell lung cancer are not well differentiated and are very aggressive; these are the ones that we are going to give systemic therapy, such as chemotherapy,” said Nagla Karim, MD, PhD, University of Cincinnati. “The typical and atypical carcinoid are well differentiated are not very aggressive.”

Treatment for Lung NETs

A lack of consensus among leading treatment guidelines complicates the diagnosis of lung NETs. (Hendifar 2017) There are also different recommendations about the need for chemotherapy and/or radiation in early-stage patients who have undergone surgery. (Hendifar 2017, Ramirez 2017) An individual’s treatment will be based on a range of factors including disease classification, stage, lymph node involvement, and tumor biomarkers. Robert Ramirez, DO, Ochsner Medical Center, stresses the importance of a multidisciplinary treatment team for lung NETs to obtain an accurate diagnosis and avoid unnecessary procedures. NETRF has compiled a list of multidisciplinary team-based programs.

The options commonly considered by a treatment team may include:
(Ramirez 2017; NCCN Guidelines Version 3.2017)

  • Surgery
  • Somatostatin analogs
  • mTOR pathway inhibitors
  • Vascular treatments
  • Chemotherapy (may be a combination of therapies)
  • Radiotherapy, such as PRRT
  • Radiation (radiofrequency ablation, stereotactic body radiation therapy or SBRT)
  • Interventional radiology (embolization)

 

Research of Lung NETs

Lung NETs were not routinely included in phase III trials for gastroenteropancreatic studies (i.e., CLARINET). The RADIANT-4 trial showed a clinical benefit of a mTOR inhibitor over placebo and led to its FDA approval for lung NETs. (Hendifar 2017)   SPINET, the first phase III study for lung NETs (NCT02683941) is underway. Participants must have a well-differentiated typical or atypical lung NET. Patients who have previously been treated with a somatostatin analog, PRRT, or more than two lines of chemotherapy/targeted therapy are excluded. Learn more about the SPINET trial in this talk by Dr. Nagla Karmin, University of Cincinnati.

 

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest

4
Leave a Reply

3 Comment threads
1 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
4 Comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  Subscribe  
newest oldest most voted
Notify of

My insurance company is denying the treatment that my doctor suggests which is cryoablation for the reason stating that there is insufficient evidence that ablation therapy is successful AND that it is not medically necessary. I have one large tumor in my left lung (about 2″ in size) and then 2 smaller tumors in the right lung. Is there any documentation in your studies on ablation therapy?

We have not funded any studies on lung tumor ablation, I am sorry to say. NCCN produces clinical guidelines for care. You have to register to view/download them. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf These do take into consideration variables like tumor grade/stage. This helpful, informative, and educational talk might also help you figure out next steps. https://www.facebook.com/norcalcarcinet/videos/1150770001739346/ Also, try looking at this article https://norcalcarcinet.org/links/81-appeal
Wishing you the best of luck,
NETRF

Kris

Is there a good resource for doctors specializing in lung NET tumor care

GB

any idea where i can get mTOR pathway inhibitors,
Vascular treatments, Radiation (radiofrequency ablation, stereotactic body radiation therapy or SBRT),
Interventional radiology (embolization) treating option in India, my Dad has pNET G1 with no SSR and no doctor is suggesting us to go for all these option they are directly suggesting Chemo. I believe we should keep Chemo as a last resort when everything stops working.

Let’s Talk About Lung NETs